Central Nervous System Tumors Clinical Trials

7 recruitingLast updated: June 18, 2026

There are 7 actively recruiting central nervous system tumors clinical trials across 2 countries. Studies span Phase 1, Phase 2. Top locations include Beijing, Beijing Municipality, China, Bethesda, Maryland, United States, Commack, New York, United States. Updated daily from ClinicalTrials.gov.


Central Nervous System Tumors Trials at a Glance

7 actively recruiting trials for central nervous system tumors are listed on ClinicalTrialsFinder across 6 cities in 2 countries. The largest study group is Phase 1 with 5 trials, with the heaviest enrollment activity in Beijing, Bethesda, and Commack. Lead sponsors running central nervous system tumors studies include Beijing InnoCare Pharma Tech Co., Ltd., Binhui Biopharmaceutical Co., Ltd., and Barbara Ann Karmanos Cancer Institute.

Browse central nervous system tumors trials by phase

Treatments under study

About Central Nervous System Tumors Clinical Trials

Looking for clinical trials for Central Nervous System Tumors? There are currently 2 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Central Nervous System Tumors trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Central Nervous System Tumors clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 17 of 7 trials

Recruiting
Phase 1Phase 2

Novel Indenoisoquinolone CMYC/TOPOISOMERASE 1 Inhibitor (LMP744) in Recurrent Glioblastoma

Brain CancerGBMGlioma+12 more
National Institute of Neurological Disorders and Stroke (NINDS)40 enrolled1 locationNCT07416188
Recruiting

Next Generation Sequencing of Normal Tissues Prospectively in Pediatric Oncology Patients

Solid, Liquid, Central Nervous System Tumors
St. Jude Children's Research Hospital2,500 enrolled1 locationNCT02530658
Recruiting
Phase 1Phase 2

A Study of Mirdametinib in People With Central Nervous System Tumors

GliomaCentral Nervous System Tumors
Memorial Sloan Kettering Cancer Center26 enrolled7 locationsNCT07539441
Recruiting
Phase 1

Neoepitope-based Personalized DNA Vaccine Approach in Pediatric Patients With Recurrent Central Nervous System Tumors

Pediatric Recurrent Central Nervous System Tumors
Washington University School of Medicine7 enrolled1 locationNCT03988283
Recruiting
Phase 1Phase 2

Study of ICP-723 in Patients With Advanced Solid Tumors or Primary Central Nervous System Tumors

Advanced Solid Tumors Harboring NTRK FusionPrimary Central Nervous System Tumors Harboring NTRK Fusion
Beijing InnoCare Pharma Tech Co., Ltd.70 enrolled1 locationNCT05745623
Recruiting
Phase 1Phase 2

OH2 Oncolytic Viral Therapy in Central Nervous System Tumors

Central Nervous System Tumors
Binhui Biopharmaceutical Co., Ltd.28 enrolled1 locationNCT05235074
Recruiting

3'-Deoxy-3'-[18F] Fluorothymidine PET Imaging in Patients With Cancer

LymphomaUnspecified Adult Solid Tumor, Protocol SpecificLeukemia+6 more
Barbara Ann Karmanos Cancer Institute1 locationNCT00935090